James Gillespie

Dr. James Gillespie

Auburn University
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
DBDeepa Bedi
Deepa Bedi
TMTiziana Musacchio
Tiziana Musacchio
OFOlusegun A. Fagbohun
Olusegun A. Fagbohun
JGJames Gillespie
James Gillespie
PDPatricia Deinnocentes
Patricia Deinnocentes
Valery A. PetrenkoValery A. Petrenko
Valery A. Petrenko

1 February 2014 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
TWTao Wang
Tao Wang
WHWilliam C. Hartner
William C. Hartner
JGJames Gillespie
James Gillespie
PKPraveen Kulkarni
Praveen Kulkarni
SYShenghong Yang
Shenghong Yang
VTVladimir P. Torchilin
Vladimir P. Torchilin

8 January 2013 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
DBDeepa Bedi
Deepa Bedi
JGJames Gillespie
James Gillespie
Andreas EbnerAndreas Ebner
Andreas Ebner
MLMichael Leitner
Michael Leitner
PHPeter Hinterdorfer
Peter Hinterdorfer
Valery A. PetrenkoValery A. Petrenko
Valery A. Petrenko

1 December 2014 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
TWTao Wang
Tao Wang
SYShenghong Yang
Shenghong Yang
LMLeslie A. Mei
Leslie A. Mei
CPChirag K. Parmar
Chirag K. Parmar
JGJames Gillespie
James Gillespie
VTVladimir P. Torchilin
Vladimir P. Torchilin
In an effort to improve the therapeutic index of cancer chemotherapy, we developed an advanced nanopreparation based on the combination of landscape phage display to obtain new targeting ligands with micellar nanoparticles for tumor targeting of water-insoluble neoplastic agents. With paclitaxel as a drug, this self-assembled nanopreparation composed of MCF-7–specific phage protein and polyethylene glycol–phosphatidylethanolamine (PEG-PE) micelles showed selective toxicity to target cancer cells rather than nontarget, non cancer cells in vitro. In vivo, the targeted phage micelles triggered a dramatic tumor reduction and extensive necrosis as a result of improved tumor delivery of paclitaxel. The enhanced anticancer effect was also verified by an enhanced apoptosis and reduced tumor cell proliferation following the treatment with the targeted micellar paclitaxel both in vitro and in vivo. The absence of hepatotoxicity and pathologic changes in tissue sections of vital organs, together with maintenance of overall health of mice following the treatment, further support its translational potential as an effective and safe chemotherapy for improved breast cancer treatment. Mol Cancer Ther; 13(12); 2864–75. ©2014 AACR.

1 August 2010 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
PJPrashanth K. Jayanna
Prashanth K. Jayanna
DBDeepa Bedi
Deepa Bedi
JGJames Gillespie
James Gillespie
PDPatricia DeInnocentes
Patricia DeInnocentes
TWTao Wang
Tao Wang
Valery A. PetrenkoValery A. Petrenko
Valery A. Petrenko

5 August 2016 in Expert Opinion on Drug Delivery
Verified
Journal Article
Closed access
Valery A. PetrenkoValery A. Petrenko
Valery A. Petrenko
JGJames Gillespie
James Gillespie
Introduction: New phage-directed nanomedicines have emerged recently as a result of the in-depth study of the genetics and structure of filamentous phage and evolution of phage display and phage nanobiotechnology. This review focuses on the progress made in the development of the cancer-targeted nanomaterials and discusses the trends in using phage as a bioselectable molecular navigation system. Areas covered: The merging of phage display technologies with nanotechnology in recent years has proved promising in different areas of medicine and technology, such as medical diagnostics, molecular imaging, vaccine development and targeted drug/gene delivery, which is the focus of this review. The authors used data obtained from their research group and sourced using Science Citation Index (Web of Science) and NCBI PubMed search resources. Expert opinion: First attempts of adapting traditional concepts of direct targeting of tumor using phage-targeted nanomedicines has shown minimal improvements. With discovery and study of biological and technical barriers that prevent anti-tumor drug delivery, a paradigm shift from traditional drug targeting to nanomedicine navigation systems is required. The advanced bacteriophage-driven self-navigation systems are thought to overcome those barriers using more precise, localized phage selection methods, multi-targeting ‘promiscuous’ ligands and advanced multifunctional nanomedicine platforms.